June #172 : HIV Meds Played Out? Deal Again. - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Patient No More

31 at 30

From the Editor

Alive and Kicking

Feedback

Letters- June 2011

The POZ Q+A

Frontline Physician

What You Need to Know

Discrimination Can’t Hide From Hidden Cameras

Bono to Obama: No Babies With HIV

No ARV in Whoonga

700,000 Stolen Condoms Recovered

LGBT People Are Greater Than AIDS, Too

HIV Testing Hits High School

AIDS Book Banned in Tennessee

HIV Goes to Sundance

Lady Gaga Wants $50M

We Hear You

Alternative View

What Matters to You

Shelter From The Storm

Treatment News

HIV Meds Played Out? Deal Again.

The Latest on Lubes and Gel

Med Breaks-Broken

Dousing the Flames

Therapeutic Vaccines

Point, Shoot, Reveal

GMHC Treatment Issues June 2011

Comfort Zone

Bubbles, Bath and Beyond

POZ Heroes

Remembering Elizabeth Taylor 1932-2011

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

June 2011

HIV Meds Played Out? Deal Again.

by Laura Whitehorn

If you have lived with HIV for a long time and have exhausted various med combos in the past, there are still options. Here are a few:

Combine three newer meds: Prezista (darunavir, boosted with Norvir) plus Intelence (etravirine) and Isentress (raltegravir), when combined with other drugs the virus may be sensitive to, suppressed HIV for some people whose HIV combos had stopped working. Most of the group still registered undetectable viral loads after two years.

Add an experimental drug: Dolutegravir (S/GSK-572) is an integrase inhibitor—a drug that prevents HIV from hijacking the genetic material in your body’s cells to reproduce. In a complete HIV regimen and taken twice a day, dolutegravir allowed some long-termers to knock HIV to undetectable levels.

Add Reyataz (atazanavir) or Invirase (saquinavir) to your combo: This helped some people who had previously taken the protease inhibitors Kaletra (lopinavir/ritonavir), Lexiva (fosamprenavir) or Agenerase (amprenavir).

Search: Prezista, Norvir, Intelence, Isentress, integrase inhibitor, Reyataz, Invirase


Scroll down to comment on this story.

email print



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    adorableone
    New York
    New York


    july8th69
    brooklyn
    New York


    TaintedloveDC
    Washington
    DC


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.